TAPUR study shows encouraging results for olaparib in BRCA-mutated advanced prostate and pancreatic cancers
The findings were presented as part of the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via